AMG 369
AMG 369 is an orally active and potent dual S1P1/S1P5 agonist with limited activity at S1P3 and no activity at S1P2/S1P4. AMG 369 reduces blood lymphocyte counts. AMG 369 delays onset and reduces severity of experimental autoimmune encephalomyelitis in rat.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1202073-26-4
- Formule: C26H22FN3O2S
- Masse moléculaire:459.54
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
S1PR1 |
S1PR5 |
S1PR3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.029 μM
Compound: 5d, AMG-369
|
Agonist activity at human S1P5R expressed in CHO cells by Ca(2+) mobilization assay
Agonist activity at human S1P5R expressed in CHO cells by Ca(2+) mobilization assay
|
[PMID: 24900288] |
| CHO | EC50 |
0.888 μM
Compound: 5d, AMG-369
|
Agonist activity at human S1P3R expressed in CHO cells by Ca(2+) mobilization assay
Agonist activity at human S1P3R expressed in CHO cells by Ca(2+) mobilization assay
|
[PMID: 24900288] |
| CHO | EC50 |
0.888 μM
Compound: AMG-369
|
Agonist activity at human S1P3 receptor expressed in CHO cells coexpressing Gq/i5 protein by calcium flux assay
Agonist activity at human S1P3 receptor expressed in CHO cells coexpressing Gq/i5 protein by calcium flux assay
|
[PMID: 22100314] |
| CHO | EC50 |
0.888 μM
Compound: AMG-369
|
Agonist activity at human S1P3 receptor expressed in CHO cells coexpressing chimeric Gq/i5 G-protein assessed as Ca2+ release by FLIPR assay
Agonist activity at human S1P3 receptor expressed in CHO cells coexpressing chimeric Gq/i5 G-protein assessed as Ca2+ release by FLIPR assay
|
[PMID: 22257889] |
| U2OS | EC50 |
0.002 μM
Compound: 5d, AMG-369
|
Induction of human GFP-tagged chimeric S1P1R internalization in human U2Os cells by fluorescence microscopy
Induction of human GFP-tagged chimeric S1P1R internalization in human U2Os cells by fluorescence microscopy
|
[PMID: 24900288] |
| U2OS | EC50 |
0.002 μM
Compound: AMG-369
|
Agonist activity at human S1P1 receptor expressed in U20S cells coexpressing eGFP assessed as receptor internalization after 1 hr by microscopy analysis
Agonist activity at human S1P1 receptor expressed in U20S cells coexpressing eGFP assessed as receptor internalization after 1 hr by microscopy analysis
|
[PMID: 22100314] |
| U2OS | EC50 |
0.002 μM
Compound: AMG-369
|
Agonist activity at eGFP-tagged human S1P1 receptor expressed in U2OS cells assessed as receptor internalization after 1 hr by Hoechst dye-based microscopic analysis
Agonist activity at eGFP-tagged human S1P1 receptor expressed in U2OS cells assessed as receptor internalization after 1 hr by Hoechst dye-based microscopic analysis
|
[PMID: 22257889] |
In Vitro
AMG 369 potently induces internalization of hS1P1-GFP fusion protein in U2OS cells with an EC50 of 0.002 μM and 98% efficacy[1].
AMG 369 weakly induces Ca2+ mobilization via hS1P3 in transfected CHO-K1 cells with an EC50 of 0.888 μM and 26% efficacy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
AMG 369 (0.1 mg/kg; p.o.; single dose) delays the onset and reduces clinical disease severity in a female Lewis rat experimental autoimmune encephalomyelitis model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats (female)[1]
-
Dosage:0.01 mg/kg; 0.03 mg/kg; 0.1 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced a non-statistically significant reduction in blood lymphocytes at 0.01 mg/kg vs vehicle.
Produced a statistically significant 45% reduction in blood lymphocytes at 0.03 mg/kg vs vehicle.
Produced a statistically significant 65% reduction in blood lymphocytes at 0.1 mg/kg vs vehicle, nearly the maximal 70% reduction typically observed with S1P1 agonists.
-
Animal Model:Lewis rats (female; experimental autoimmune encephalomyelitis model induced by guinea pig myelin basic protein immunization)[1]
-
Dosage:0.01 mg/kg; 0.1 mg/kg
-
Administration:p.o.; single dose
-
Result:Did not significantly impact clinical disease scores at 0.01 mg/kg vs vehicle.
Delayed disease onset and produced a statistically significant reduction in clinical disease scores at 0.1 mg/kg vs vehicle.
Chemical Information
-
CAS No. 1202073-26-4
-
Masse moléculaire 459.54
-
Formule C26H22FN3O2S
-
SMILES
O=C(O)C1CN(CC2=CC=C(C(F)=C2)C3=NC=4C=CC(=NC4S3)C5(C=6C=CC=CC6)CC5)C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)